A Phase 3 interventional study of MenABCWY vaccine and Placebo in Meningitis, Meningococcal, sponsored by GlaxoSmithKline. Completed at 69 sites in 4 countries. Open to participants aged 15 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-03.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Meningitis, Meningococcal with a site in United States — none open to participants now, 1 under way, none of them phase 3. Meningitis, Meningococcal · United States.
Among the 36 studies in Meningitis, Meningococcal with a site in United States, this one is the 9th largest by enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2021, is one of 16 in phase 3, and was the 35th registered.
125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.
Browse Meningitis, Meningococcal studies →None of the 36 studies in Meningitis, Meningococcal with a site in United States is open now. The open studies under Meningitis, Meningococcal, anywhere →
Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 15 Years to 25 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 11 · Phase 3 16 · Phase 4 2
First in 2005; this study’s year is marked. 2 started in 2021.
This study's enrollment of 1,250 is above the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.
Median enrollment 751 across the 33 interventional studies, 393 across the 3 observational. Of the 35 that completed or were terminated, 29 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 36 have an industry lead sponsor. The 9 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 117 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 242 (90%) have results posted.
GlaxoSmithKline has 9 studies filed under Meningitis, Meningococcal — fewer than ten, so there is no comparison to draw.
1 of the studies in Meningitis, Meningococcal with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05087056GlaxoSmithKlineSafety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents | 2027-03-10 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies in Meningitis, Meningococcal with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to assess immunogenicity and safety of MenABCWY vaccine in healthy adolescents and adults aged 15 to 25 years previously vaccinated with MenACWY vaccine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female participants of childbearing potential may be enrolled in the study, if the participant:
Exclusion Criteria:
Abnormal function or modification of the immune system resulting from:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 2 doses of the MenABCWY vaccine on Day 1 and Day 181 (0,6-month schedule) and 1 dose of placebo on Day 211.
Combination Product: MenABCWY vaccine · Combination Product: Placebo
Participants received 1 dose of MenACWY vaccine on Day 1 and 2 doses of MenB vaccine on Day 181 and Day 211.
Biological: MenACWY vaccine · Combination Product: MenB vaccine
2 doses of MenABCWY vaccine administered intramuscularly on Day 1 and Day 181 to participants in ABCWY group.
1 dose of placebo administered intramuscularly on Day 211 to participants in ABCWY group
1 dose of MenACWY vaccine administered intramuscularly on Day 1 to participants in ACWY group
Also known as: Menveo
2 doses of MenB vaccine administered intramuscularly on Day 181 and Day 211 to participants in ACWY group. MenB vaccine is a non-investigational medical product (NIMP) in this study and is administered only in compliance with standard of care.
Also known as: Bexsero
Percentages of Participants With a 4-fold Rise in Human Serum Bactericidal Assay (hSBA) Titers Against N. Meningitidis Serogroups A, C, W, and Y at 1 Month After the Second MenABCWY Vaccination and the Single MenACWY Vaccination, Relative to Baseline
Four-fold rise is defined as: - a post-vaccination hSBA titer equal to or higher than (\>=) 16 for participants with a pre-vaccination hSBA titer \<4; - a post-vaccination hSBA titer \>= 4 times the LLOQ for participants with a pre vaccination hSBA titer \>= limit of detection (LOD) but \< LLOQ; and - a post-vaccination hSBA titer \>= 4 times the pre-vaccination titer for participants with a pre-vaccination hSBA titer \>= LLOQ.
Time frame: At 1 month after vaccination schedule (i.e., Day 211 for ABCWY group and Day 31 for ACWY group) compared to Day 1 (Baseline)
Percentages of Participants With a 4-fold Rise in hSBA Titers Against N. Meningitidis Serogroups A, C, W, and Y at 1 Month After the First MenABCWY Vaccination and the Single MenACWY Vaccination, Relative to Baseline
Four-fold rise is defined as: - a post-vaccination hSBA titer equal to or higher than (\>=) 16 for participants with a pre-vaccination hSBA titer \<4; - a post-vaccination hSBA titer \>= 4 times the LLOQ for participants with a pre vaccination hSBA titer \>= limit of detection (LOD) but \< LLOQ; and - a post-vaccination hSBA titer \>= 4 times the pre-vaccination titer for participants with a pre-vaccination hSBA titer \>= LLOQ.
Time frame: At 1 month after the first vaccination (i.e., Day 31) compared to Day 1 (Baseline)
Number of Participants With Solicited Administration Site Events Following Vaccination at Day 1 for ABCWY Group and ACWY Group
Assessed solicited administration site events include injection site pain, erythema, swelling, induration. Any pain = occurrence of the symptom regardless of intensity grade and any erythema, swelling and induration are defined as a symptom with a surface diameter equal to or greater than 25 millimeters.
Time frame: During the 7 days (including day of vaccination) following vaccination at day 1 for ABCWY group and ACWY group
Number of Participants With Solicited Administration Site Events Following Vaccination at Day 181 for ABCWY Group
Assessed solicited administration site events include injection site pain, erythema, swelling, induration. Any pain = occurrence of the symptom regardless of intensity grade and any erythema, swelling and induration are defined as a symptom with a surface diameter equal to or greater than 25 millimeters.
Time frame: During the 7 days (including day of vaccination) following vaccination at Day 181 for ABCWY group
Number of Participants With Solicited Systemic Events Following Vaccination at Day 1 for the ABCWY Group and ACWY Group
Assessed solicited systemic events include fever \[body temperature \>= 38.0°C (celsius) /100.4°F (Fahrenheit)\], nausea, fatigue, myalgia, arthralgia, headache.
Time frame: During the 7 days (including day of vaccination) following vaccination at day 1 for the ABCWY group and ACWY group
Number of Participants With Solicited Systemic Events Following Vaccination at Day 181 for the ABCWY Group
Assessed solicited systemic events include fever \[body temperature \>= 38.0°C/100.4°F\], nausea, fatigue, myalgia, arthralgia, headache.
Time frame: During the 7 days (including day of vaccination) following vaccination at day 181 for the ABCWY group
Number of Participants With Any Unsolicited Adverse Events (AEs) (Including All Serious Adverse Events [SAEs], AEs Leading to Withdrawal, AEs of Special Interest [AESIs] and Medically Attended AEs)
Unsolicited AE-AE not solicited using an eDiary and spontaneously communicated by a participant/participant's parent(s)/Legally acceptable representative(s) who has signed informed consent. SAEs-events that result in death, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is congenital anomaly/birth defect in the offspring of a study participant/results in abnormal pregnancy outcomes. AESIs-predefined AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterize and understand it. An MAE is defined as an unsolicited AE for which the participant received medical attention such as hospitalization, or an emergency room visit, or visit to/by a health care provider.
Time frame: During the 30 days (including day of vaccination) following vaccination at day 1 for ABCWY group and ACWY group
Number of Participants With Any Unsolicited Adverse Events (AEs) (Including All Serious Adverse Events [SAEs], AEs Leading to Withdrawal, AEs of Special Interest [AESIs] and Medically Attended AEs) Following Vaccination at Day 181 for ABCWY Group
Any AE-untoward medical occurrence in a patient/clinical investigation participant, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. Unsolicited AE-AE not solicited using an eDiary and spontaneously communicated by a participant/participant's parent(s)/Legally acceptable representative(s) who has signed informed consent. SAEs-events that result in death, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is congenital anomaly/birth defect in the offspring of a study participant/results in abnormal pregnancy outcomes. AESIs-predefined AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterize and understand it.
Time frame: During the 30 days (including day of vaccination) following vaccination at day 181 for ABCWY group
Number of Participants With SAEs, AEs Leading to Withdrawal, AESIs and Medically Attended AEs
SAEs, AEs leading to withdrawal, AESIs and medically attended AEs were assessed throughout the study period are reported in this outcome measure.
Time frame: From Day 1 to Day 361 (throughout the study period)
Percentages of Participants With hSBA Titers >= Lower Limit of Quantitation (LLOQ) Against Serogroups A, C, W, and Y at Day 1, 1 Month After the First MenABCWY Vaccination and After the Single MenACWY Vaccination
The immune response to MenABCWY vaccine after the first dose and single dose of MenACWY vaccine was evaluated by measuring the percentage of participants with hSBA titers \>= LLOQ against each of the serogroups A, C, W and Y.
Time frame: At Day 1 (pre-vaccination) and 1 month after the vaccination schedule (i.e., Day 31 for ABCWY group [first dose] and ACWY group)
Percentages of Participants With hSBA Titers >= Lower Limit of Quantitation (LLOQ) Against Serogroups A, C, W, and Y at 1 Month After the Second MenABCWY Vaccination
The immune response to MenABCWY vaccine after the second dose was evaluated by measuring the percentage of participants with hSBA titers \>= LLOQ against each of the serogroups A, C, W and Y.
Time frame: 1 month after the vaccination schedule (i.e., Day 211 for ABCWY group [second dose])
hSBA Geometric Mean Titers (GMTs) Against Serogroups A, C, W, and Y at Day 1, 1 Month After the First MenABCWY Vaccination and After the Single MenACWY Vaccination
The immune response to MenABCWY after first dose and single dose of MenACWY vaccine was evaluated by measuring the human serum bactericidal activity against each of the serogroups A, C, W and Y in terms of GMTs. For each serogroup, the GMTs with their associated 2-sided 95% confidence intervals were calculated.
Time frame: At Day 1 and 1 month after the vaccination schedule (i.e., Day 31 for ABCWY group [first dose] and ACWY group)
hSBA Geometric Mean Titers (GMTs) Against Serogroups A, C, W, and Y at 1 Month After the Second MenABCWY Vaccination
The immune response to MenABCWY after second dose was evaluated by measuring the human serum bactericidal activity against each of the serogroups A, C, W and Y in terms of GMTs. For each serogroup, the GMTs with their associated 2-sided 95% confidence intervals were calculated.
Time frame: 1 month after the vaccination schedule (i.e., Day 211 for ABCWY group [second dose])
Geometric Mean Ratios (GMRs) Against Serogroups A, C, W, and Y at 1 Month After the First MenABCWY Vaccination and After the Single MenACWY Vaccination
The immune response to MenABCWY vaccine after first and single dose of MenACWY vaccine are evaluated by measuring the human serum bactericidal activity against each of the serogroups A, C, W and Y, compared to baseline (Day 1) and expressed as GMRs. Within group GMRs was calculated as ratio of GMTs in the post-vaccination timepoint to the pre-vaccination timepoint.
Time frame: At 1 month after the vaccination schedule (i.e., Day 31 for ABCWY group [first dose] and ACWY group) compared to baseline (Day 1)
Geometric Mean Ratios (GMRs) Against Serogroups A, C, W, and Y at 1 Month After Second MenABCWY Vaccination
The immune response to MenABCWY vaccine after second dose are evaluated by measuring the human serum bactericidal activity against each of the serogroups A, C, W and Y, compared to baseline (Day 1) and expressed as GMRs. Within group GMRs was calculated as ratio of GMTs in the post-vaccination timepoint to the pre-vaccination timepoint.
Time frame: At 1 month after the vaccination schedule (i.e., Day 211 for ABCWY group [second dose]) compared to baseline (Day 1)
Percentages of Participants With hSBA Titers >= LLOQ for Each and All Serogroup B Indicator Strains at Day 1 and at 1 Month After the Second Dose of MenABCWY Vaccination
The immune response to MenABCWY vaccine after second dose was evaluated by measuring bactericidal activity against each (individual response) and all (composite response) N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively).
Time frame: At Day 1 and at Day 211
Percentages of Participants With 4-fold Rise in hSBA Titers Against Each N. Meningitidis Serogroup B Indicator Strains at 1 Month After the Second MenABCWY Vaccination
The immune response to MenABCWY after second dose is evaluated by measuring bactericidal activity against each of the N. meningitidis serogroup B test strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively). compared to baseline (day 1) in terms of 4-fold rise in hSBA titers. For each of the serogroup B indicator strains, the 4-fold rise is defined as: a post-vaccination hSBA titer \>=16 for participants with a pre-vaccination hSBA titer \<4; . a post-vaccination hSBA titer \>= 4 times the LLOQ for participants with a prevaccination hSBA titer \>= limit of detection (LOD) but \< LLOQ; and, a post-vaccination hSBA titer \>= 4 times the pre-vaccination titer for participants with a pre-vaccination hSBA titer \>= LLOQ.
Time frame: At Day 211 compared to baseline (Day 1)
GMTs Against Each Serogroup B Indicator Strains at Day 1 and at 1 Month After Second MenABCWY Vaccination
The immune response to MenABCWY vaccine after the second dose was evaluated by measuring bactericidal activity against each of the N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively) in terms of GMTs at baseline (Day 1) and 1 month after second MenABCWY vaccination.
Time frame: At Day 1 and at Day 211
GMRs Against Each Serogroup B Indicator Strains at 1 Month After Second Dose of MenABCWY Vaccination
The immune response to MenABCWY vaccine after second dose was evaluated by measuring the human serum bactericidal activity against each of the N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively) compared to baseline (Day 1) and expressed as GMRs. Within group GMRs was calculated as ratio of GMTs in the post-vaccination timepoint to the pre-vaccination timepoint.
Time frame: At Day 211 compared to baseline (Day 1)
Out of 1250 participants enrolled,3 participants did not receive vaccination as they did not meet the eligibility criteria, therefore only 1247 participants were included in the Exposed Set and started the study.
| Milestone | ABCWY Group | ACWY Group |
|---|---|---|
| Started | 626 | 621 |
| Completed | 541 | 542 |
| Not completed | 85 | 79 |
| Withdrew: Adverse event | 5 | 8 |
| Withdrew: Lost to follow-up | 44 | 31 |
| Withdrew: Protocol violation | 1 | 5 |
| Withdrew: Withdrawal by subject | 27 | 25 |
| Withdrew: Migrated / moved from the study area | 8 | 8 |
| Withdrew: Other | 0 | 2 |
Four-fold rise is defined as: - a post-vaccination hSBA titer equal to or higher than (\>=) 16 for participants with a pre-vaccination hSBA titer \<4; - a post-vaccination hSBA titer \>= 4 times the LLOQ for participants with a pre vaccination hSBA titer \>= limit of detection (LOD) but \< LLOQ; and - a post-vaccination hSBA titer \>= 4 times the pre-vaccination titer for participants with a pre-vaccination hSBA titer \>= LLOQ.
| Percentage of Participants | ABCWY Group | ACWY Group |
|---|---|---|
| Meningitis A | 95.3 (90.89 to 97.93) | 95.0 (92.78 to 96.77) |
| Meningitis C | 94.5 (90.07 to 97.32) | 94.0 (91.62 to 95.80) |
| Meningitis W | 95.6 (91.48 to 98.07) | 93.9 (91.59 to 95.79) |
| Meningitis Y | 95.0 (90.72 to 97.69) | 94.4 (92.12 to 96.20) |
Four-fold rise is defined as: - a post-vaccination hSBA titer equal to or higher than (\>=) 16 for participants with a pre-vaccination hSBA titer \<4; - a post-vaccination hSBA titer \>= 4 times the LLOQ for participants with a pre vaccination hSBA titer \>= limit of detection (LOD) but \< LLOQ; and - a post-vaccination hSBA titer \>= 4 times the pre-vaccination titer for participants with a pre-vaccination hSBA titer \>= LLOQ.
| Percentage of Participants | ABCWY Group | ACWY Group |
|---|---|---|
| Meningitis A | 92.5 (89.90 to 94.66) | 95.0 (92.78 to 96.77) |
| Meningitis C | 94.0 (91.76 to 95.83) | 94.0 (91.62 to 95.80) |
| Meningitis W | 94.3 (92.10 to 96.09) | 93.9 (91.59 to 95.79) |
| Meningitis Y | 93.7 (91.32 to 95.51) | 94.4 (92.12 to 96.20) |
Assessed solicited administration site events include injection site pain, erythema, swelling, induration. Any pain = occurrence of the symptom regardless of intensity grade and any erythema, swelling and induration are defined as a symptom with a surface diameter equal to or greater than 25 millimeters.
| Participants | ABCWY Group | ACWY Group |
|---|---|---|
| Injection site pain | 486 | 191 |
| Erythema | 29 | 9 |
| Swelling | 26 | 13 |
| Induration | 24 | 14 |
Assessed solicited administration site events include injection site pain, erythema, swelling, induration. Any pain = occurrence of the symptom regardless of intensity grade and any erythema, swelling and induration are defined as a symptom with a surface diameter equal to or greater than 25 millimeters.
| Participants | ABCWY Group |
|---|---|
| Injection site pain | 377 |
| Erythema | 31 |
| Swelling | 30 |
| Induration | 22 |
Assessed solicited systemic events include fever \[body temperature \>= 38.0°C (celsius) /100.4°F (Fahrenheit)\], nausea, fatigue, myalgia, arthralgia, headache.
| Participants | ABCWY Group | ACWY Group |
|---|---|---|
| Fever | 12 | 7 |
| Nausea | 88 | 75 |
| Fatigue | 244 | 222 |
| Myalgia | 90 | 66 |
| Arthralgia | 45 | 49 |
| Headache | 249 | 208 |
Assessed solicited systemic events include fever \[body temperature \>= 38.0°C/100.4°F\], nausea, fatigue, myalgia, arthralgia, headache.
| Participants | ABCWY Group |
|---|---|
| Fever | 9 |
| Nausea | 58 |
| Fatigue | 167 |
| Myalgia | 67 |
| Arthralgia | 30 |
| Headache | 167 |
Unsolicited AE-AE not solicited using an eDiary and spontaneously communicated by a participant/participant's parent(s)/Legally acceptable representative(s) who has signed informed consent. SAEs-events that result in death, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is congenital anomaly/birth defect in the offspring of a study participant/results in abnormal pregnancy outcomes. AESIs-predefined AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterize and understand it. An MAE is defined as an unsolicited AE for which the participant received medical attention such as hospitalization, or an emergency room visit, or visit to/by a health care provider.
| Participants | ABCWY Group | ACWY Group |
|---|---|---|
| Number of Participants With Any Unsolicited Adverse Events (AEs) (Including All Serious Adverse Events [SAEs], AEs Leading to Withdrawal, AEs of Special Interest [AESIs] and Medically Attended AEs) | 96 | 93 |
Any AE-untoward medical occurrence in a patient/clinical investigation participant, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. Unsolicited AE-AE not solicited using an eDiary and spontaneously communicated by a participant/participant's parent(s)/Legally acceptable representative(s) who has signed informed consent. SAEs-events that result in death, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is congenital anomaly/birth defect in the offspring of a study participant/results in abnormal pregnancy outcomes. AESIs-predefined AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterize and understand it.
| Participants | ABCWY Group |
|---|---|
| Number of Participants With Any Unsolicited Adverse Events (AEs) (Including All Serious Adverse Events [SAEs], AEs Leading to Withdrawal, AEs of Special Interest [AESIs] and Medically Attended AEs) Following Vaccination at Day 181 for ABCWY Group | 72 |
SAEs, AEs leading to withdrawal, AESIs and medically attended AEs were assessed throughout the study period are reported in this outcome measure.
| Participants | ABCWY Group | ACWY Group |
|---|---|---|
| SAEs | 18 | 7 |
| AEs leading to withdrawal | 4 | 6 |
| AESIs | 0 | 4 |
| Medically Attended AEs | 223 | 206 |
The immune response to MenABCWY vaccine after the first dose and single dose of MenACWY vaccine was evaluated by measuring the percentage of participants with hSBA titers \>= LLOQ against each of the serogroups A, C, W and Y.
| Percentage of Participants | ABCWY Group | ACWY Group |
|---|---|---|
| Meningitis A, Day 1 | 27.7 (23.94 to 31.61) | 28.8 (25.02 to 32.77) |
| Meningitis A, Day 31 | 98.3 (96.98 to 99.20) | 98.1 (96.66 to 99.06) |
| Meningitis C, Day 1 | 57.7 (53.67 to 61.72) | 56.2 (52.03 to 60.23) |
| Meningitis C, Day 31 | 98.9 (97.65 to 99.54) | 99.0 (97.81 to 99.63) |
| Meningitis W, Day 1 | 36.3 (32.48 to 40.35) | 33.4 (29.62 to 37.44) |
| Meningitis W, Day 31 | 98.4 (96.99 to 99.21) | 96.8 (95.03 to 98.06) |
| Meningitis Y, Day 1 | 37.5 (33.61 to 41.51) | 34.9 (31.00 to 38.94) |
| Meningitis Y, Day 31 | 97.9 (96.36 to 98.85) | 97.6 (96.06 to 98.70) |
The immune response to MenABCWY vaccine after the second dose was evaluated by measuring the percentage of participants with hSBA titers \>= LLOQ against each of the serogroups A, C, W and Y.
| Percentage of Participants | ABCWY Group |
|---|---|
| Meningitis A, Day 211 | 99.5 (97.41 to 99.99) |
| Meningitis C, Day 211 | 100.0 (98.27 to 100.00) |
| Meningitis W, Day 211 | 100.0 (98.28 to 100.00) |
| Meningitis Y, Day 211 | 100.0 (98.26 to 100.00) |
The immune response to MenABCWY after first dose and single dose of MenACWY vaccine was evaluated by measuring the human serum bactericidal activity against each of the serogroups A, C, W and Y in terms of GMTs. For each serogroup, the GMTs with their associated 2-sided 95% confidence intervals were calculated.
| Titers | ABCWY Group | ACWY Group |
|---|---|---|
| Meningitis A, Day 1 | 15.30 (13.07 to 17.92) | 16.34 (13.96 to 19.14) |
| Meningitis A, Day 31 | 670.78 (594.71 to 756.58) | 1282.56 (1135.84 to 1448.23) |
| Meningitis C, Day 1 | 31.90 (26.63 to 38.23) | 29.76 (24.81 to 35.71) |
| Meningitis C, Day 31 | 2945.68 (2471.13 to 3511.36) | 2552.27 (2138.66 to 3045.87) |
| Meningitis W, Day 1 | 12.08 (10.31 to 14.15) | 11.08 (9.45 to 12.99) |
| Meningitis W, Day 31 | 1899.60 (1638.73 to 2202.00) | 1665.64 (1435.57 to 1932.58) |
| Meningitis Y, Day 1 | 12.84 (11.16 to 14.76) | 11.86 (10.29 to 13.66) |
| Meningitis Y, Day 31 | 1590.71 (1380.78 to 1832.55) | 1578.42 (1369.00 to 1819.88) |
The immune response to MenABCWY after second dose was evaluated by measuring the human serum bactericidal activity against each of the serogroups A, C, W and Y in terms of GMTs. For each serogroup, the GMTs with their associated 2-sided 95% confidence intervals were calculated.
| Titers | ABCWY Group |
|---|---|
| Meningitis A, Day 211 | 645.24 (544.11 to 765.16) |
| Meningitis C, Day 211 | 2350.14 (1809.69 to 3052.00) |
| Meningitis W, Day 211 | 1173.61 (940.25 to 1464.89) |
| Meningitis Y, Day 211 | 1130.54 (916.85 to 1394.04) |
The immune response to MenABCWY vaccine after first and single dose of MenACWY vaccine are evaluated by measuring the human serum bactericidal activity against each of the serogroups A, C, W and Y, compared to baseline (Day 1) and expressed as GMRs. Within group GMRs was calculated as ratio of GMTs in the post-vaccination timepoint to the pre-vaccination timepoint.
| Ratio | ABCWY Group | ACWY Group |
|---|---|---|
| Meningitis A, Day 31 | 43.98 (36.92 to 52.40) | 76.91 (64.53 to 91.66) |
| Meningitis C, Day 31 | 92.87 (77.13 to 111.83) | 86.36 (71.63 to 104.12) |
| Meningitis W, Day 31 | 154.09 (125.80 to 188.73) | 150.83 (123.00 to 184.96) |
| Meningitis Y, Day 31 | 124.11 (103.23 to 149.23) | 134.66 (111.75 to 162.26) |
The immune response to MenABCWY vaccine after second dose are evaluated by measuring the human serum bactericidal activity against each of the serogroups A, C, W and Y, compared to baseline (Day 1) and expressed as GMRs. Within group GMRs was calculated as ratio of GMTs in the post-vaccination timepoint to the pre-vaccination timepoint.
| Ratio | ABCWY Group |
|---|---|
| Meningitis A, Day 211 | 44.74 (34.67 to 57.74) |
| Meningitis C, Day 211 | 68.33 (52.19 to 89.46) |
| Meningitis W, Day 211 | 97.66 (72.52 to 131.52) |
| Meningitis Y, Day 211 | 82.45 (62.80 to 108.24) |
The immune response to MenABCWY vaccine after second dose was evaluated by measuring bactericidal activity against each (individual response) and all (composite response) N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively).
| Percentage of Participants | ABCWY Group |
|---|---|
| fHbp (M14459) Ab, Day 1 | 8.7 (5.05 to 13.74) |
| fHbp (M14459) Ab, Day 211 | 88.5 (82.60 to 92.92) |
| NadA (96217) Ab, Day 1 | 7.7 (4.25 to 12.50) |
| NadA (96217) Ab, Day 211 | 95.8 (91.45 to 98.28) |
| NHBA (M13520) Ab, Day 1 | 20.2 (14.65 to 26.77) |
| NHBA (M13520) Ab, Day 211 | 96.3 (92.21 to 98.65) |
| PorAP1.4 (NZ98/254) Ab, Day 1 | 2.7 (0.89 to 6.23) |
| PorAP1.4 (NZ98/254) Ab, Day 211 | 75.6 (68.30 to 81.97) |
| Composite Response, Day 1 | 1.1 (0.13 to 3.93) |
| Composite Response, Day 211 | 72.0 (64.41 to 78.68) |
The immune response to MenABCWY after second dose is evaluated by measuring bactericidal activity against each of the N. meningitidis serogroup B test strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively). compared to baseline (day 1) in terms of 4-fold rise in hSBA titers. For each of the serogroup B indicator strains, the 4-fold rise is defined as: a post-vaccination hSBA titer \>=16 for participants with a pre-vaccination hSBA titer \<4; . a post-vaccination hSBA titer \>= 4 times the LLOQ for participants with a prevaccination hSBA titer \>= limit of detection (LOD) but \< LLOQ; and, a post-vaccination hSBA titer \>= 4 times the pre-vaccination titer for participants with a pre-vaccination hSBA titer \>= LLOQ.
| Percentage of Participants | ABCWY Group |
|---|---|
| fHbp (M14459) Ab | 68.1 (60.35 to 75.17) |
| NadA (96217) Ab | 90.1 (84.46 to 94.25) |
| NHBA (M13520) Ab | 64.6 (56.68 to 71.96) |
| PorAP1.4 (NZ98/254) Ab | 45.7 (37.84 to 53.68) |
The immune response to MenABCWY vaccine after the second dose was evaluated by measuring bactericidal activity against each of the N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively) in terms of GMTs at baseline (Day 1) and 1 month after second MenABCWY vaccination.
| Titers | ABCWY Group |
|---|---|
| fHbp (M14459) Ab, Day 1 | 2.84 (2.53 to 3.19) |
| fHbp (M14459) Ab, Day 211 | 17.56 (13.52 to 22.80) |
| NadA (96217) Ab, Day 1 | 8.62 (7.39 to 10.06) |
| NadA (96217) Ab, Day 211 | 143.61 (106.71 to 193.26) |
| NHBA (M13520) Ab, Day 1 | 3.28 (2.59 to 4.15) |
| NHBA (M13520) Ab, Day 211 | 24.82 (19.19 to 32.11) |
| PorAP1.4 (NZ98/254) Ab, Day 1 | 3.13 (2.86 to 3.43) |
| PorAP1.4 (NZ98/254) Ab, Day 211 | 11.44 (8.61 to 15.19) |
The immune response to MenABCWY vaccine after second dose was evaluated by measuring the human serum bactericidal activity against each of the N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively) compared to baseline (Day 1) and expressed as GMRs. Within group GMRs was calculated as ratio of GMTs in the post-vaccination timepoint to the pre-vaccination timepoint.
| Ratio | ABCWY Group |
|---|---|
| fHbp (M14459) Ab | 6.29 (4.84 to 8.18) |
| NadA (96217) Ab | 16.67 (12.25 to 22.70) |
| NHBA (M13520) Ab | 7.69 (6.08 to 9.72) |
| PorAP1.4 (NZ98/254) Ab | 3.65 (2.76 to 4.83) |
Collected over Solicited AEs were collected during the 7-day follow-up period after vaccination. Unsolicited AEs were collected during the 30-day follow-up period after vaccination. SAEs were collected through the entire period of the study (from Day 1 up to study end [Day 361]). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ABCWY Group | 1/626 (0.2%) | 18/626 (2.9%) | 583/626 (93.1%) |
| ACWY Group | 1/621 (0.2%) | 7/621 (1.1%) | 552/621 (88.9%) |
| Event | ABCWY Group | ACWY Group |
|---|---|---|
| Pilonidal diseaseInfections and infestations | 1/626 | 2/621 |
| AppendicitisInfections and infestations | 2/626 | 0/621 |
| Suicidal ideationPsychiatric disorders | 2/626 | 0/621 |
| Bipolar disorderPsychiatric disorders | 0/626 | 1/621 |
| Completed suicidePsychiatric disorders | 1/626 | 1/621 |
| DepressionPsychiatric disorders | 0/626 | 1/621 |
| Intentional self-injuryPsychiatric disorders | 0/626 | 1/621 |
| GastroschisisCongenital, familial and genetic disorders | 0/626 | 1/621 |
| Joint injuryInjury, poisoning and procedural complications | 0/626 | 1/621 |
| Norovirus infectionInfections and infestations | 1/626 | 0/621 |
| Event | ABCWY Group | ACWY Group |
|---|---|---|
| Administration site painGeneral disorders | 524/626 | 455/621 |
| HeadacheNervous system disorders | 323/626 | 291/621 |
| FatigueGeneral disorders | 318/626 | 293/621 |
| MyalgiaMusculoskeletal and connective tissue disorders | 139/626 | 113/621 |
| NauseaGastrointestinal disorders | 132/626 | 124/621 |
| COVID-19Infections and infestations | 92/626 | 97/621 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 71/626 | 78/621 |
| Administration site indurationGeneral disorders | 54/626 | 40/621 |
| Administration site erythemaGeneral disorders | 53/626 | 30/621 |
| Administration site swellingGeneral disorders | 49/626 | 37/621 |
| Age, Continuous(YEARS) | ABCWY Group | ACWY Group | Total |
|---|---|---|---|
| Mean | 17.2 ± 2.53 | 17.2 ± 2.63 | 17.2 ± 2.58 |
| Sex: Female, Male(Participants) | ABCWY Group | ACWY Group | Total |
|---|---|---|---|
| Female | 343 | 324 | 667 |
| Male | 283 | 297 | 580 |
| Race/Ethnicity, Customized(Participants) | ABCWY Group | ACWY Group | Total |
|---|---|---|---|
| Black or African American | 94 | 86 | 180 |
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 22 | 33 | 55 |
| Native Hawaiian or Other Pacific Islander | 2 | 6 | 8 |
| White | 474 | 464 | 938 |
| Other UNSPECIFIED | 33 | 31 | 64 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Ran from Jan 2021 to primary completion in May 2023, 27 months.
Results were first posted in Jul 2024, 1 year 2 months after primary completion.
Of 25 phase 3 interventional studies under Meningitis, Meningococcal, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 20. This study's 27 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.